TScan Therapeutics (TCRX) Stock Price, News & Analysis

Company Overview

TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of T cell receptor (TCR)-based immunotherapies for cancer. Leveraging its proprietary T-Scan® platform, the company identifies and validates tumor-specific antigens presented on the surface of cancer cells. By coupling high-throughput screening with advanced computational analytics, TScan aims to develop next-generation TCR therapies capable of targeting a broad array of solid tumor indications with precision and durability.

The company’s lead pipeline candidates include autologous and allogeneic TCR-engineered T cell programs directed at well-validated cancer antigens. Preclinical data have demonstrated potent and selective cytotoxic activity against tumor cell lines, paving the way for planned IND submissions and early-phase clinical trials. TScan is also exploring multiplex engineering approaches to enhance T cell persistence, safety and tumor infiltration, positioning its portfolio for potential differentiation in a competitive immuno-oncology landscape.

Founded in 2018 and headquartered in Cambridge, Massachusetts, TScan emerged from pioneering research at leading academic institutions. The company completed a public listing on the Nasdaq exchange in August 2021 under the ticker TCRX, raising capital to advance its discovery engine and clinical pipeline. Under the leadership of President and Chief Executive Officer James J. Mastrianni, Ph.D., and Chief Scientific Officer Marcela Varela, Ph.D., TScan has assembled a multidisciplinary team of immunologists, molecular biologists and translational scientists.

In addition to its internal programs, TScan has forged research collaborations and strategic partnerships to broaden the application of its TCR platform across multiple cancer types. While its primary operations are in the United States, the company is actively exploring global development plans and regulatory pathways to extend the reach of its immuno-oncology innovations to patients worldwide.

Key Stats

• Today's Range: $1.72 to $1.90
• 50-Day Range: $1.21 to $1.84
• 52-Week Range: $1.02 to $7.89
• Volume: 493,368 shs
• Average Volume: 410,204 shs
• Market Capitalization: $104.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.80
• Consensus Rating: Buy

TScan Therapeutics Stock Analysis - MarketRank™

TScan Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 461st out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

TScan Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

TScan Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for TScan Therapeutics are expected to decrease in the coming year, from ($1.12) to ($1.14) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TScan Therapeutics is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of TScan Therapeutics is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

TScan Therapeutics has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.18% of the float of TScan Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

TScan Therapeutics has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in TScan Therapeutics has recently increased by 12.94%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TScan Therapeutics does not currently pay a dividend.

Dividend Growth

TScan Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.18% of the float of TScan Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

TScan Therapeutics has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in TScan Therapeutics has recently increased by 12.94%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.59

News Sentiment

TScan Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for TScan Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for TCRX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added TScan Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, TScan Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,106,553.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 4.35% of the stock of TScan Therapeutics is held by insiders.

Percentage Held by Institutions

82.83% of the stock of TScan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TCRX Stock Analysis - Frequently Asked Questions

How have TCRX shares performed this year?

TScan Therapeutics' stock was trading at $3.04 at the beginning of the year. Since then, TCRX shares have decreased by 39.5% and is now trading at $1.84.

How were TScan Therapeutics' earnings last quarter?

TScan Therapeutics, Inc. (NASDAQ:TCRX) posted its quarterly earnings data on Monday, May, 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.02. The firm had revenue of $2.17 million for the quarter, compared to analysts' expectations of $1.62 million. TScan Therapeutics had a negative trailing twelve-month return on equity of 55.76% and a negative net margin of 2,974.08%.

When did TScan Therapeutics IPO?

TScan Therapeutics (TCRX) raised $100 million in an IPO on Friday, July 16th 2021. The company issued 6,250,000 shares at a price of $15.00-$17.00 per share.

How do I buy shares of TScan Therapeutics?

Shares of TCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TScan Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TScan Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TCRX
• CIK: 1783328
• Web: www.tscan.com
• Phone: 857-399-9500
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for TScan Therapeutics: $7.80
• High Price Target: $10.00
• Low Price Target: $3.00
• Potential Upside/Downside: +323.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$127.50 million
• Net Margins: -2,974.08%
• Pretax Margin: -2,974.08%
• Return on Equity: -55.76%
• Return on Assets: -36.56%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 8.55
• Quick Ratio: 8.55

Sales & Book Value

• Annual Sales: $2.82 million
• Price / Sales: 36.92
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.26 per share
• Price / Book: 0.43

Miscellaneous

• Outstanding Shares: 56,590,000
• Free Float: 54,129,000
• Market Cap: $104.13 million
• Optionable: Not Optionable
• Beta: 0.97